Claas F H, de Fraiture W H, Meyboom R H
Nouv Rev Fr Hematol (1978). 1984;26(5):323-4.
Ticlopidine is a new drug for the inhibition of the aggregation of platelets, which is used in arteriosclerosis. Here we describe a patient, who developed a thrombocytopenic purpura whilst using this drug. After stopping the drug, platelet counts normalized in two weeks. In the serum of this patient antibodies were found which reacted with the Ticlopidine exposed platelets of the patient after recovery and with those of healthy donors. These antibodies did not react when these platelets were exposed to tetrahydro-4,5,6,7,thiéno(3,2-c)pyridine, a metabolite of Ticlopidine. We conclude that after adherence of the drug to the platelet membrane, antibodies induced by Ticlopidine destroy the platelets as carriers of the drug.
噻氯匹定是一种用于抑制血小板聚集的新药，用于治疗动脉硬化。本文描述了一名患者，在使用该药期间发生了血小板减少性紫癜。停药后，血小板计数在两周内恢复正常。在该患者的血清中发现了抗体，这些抗体在患者康复后与暴露于噻氯匹定的血小板以及健康供体的血小板发生反应。当这些血小板暴露于噻氯匹定的代谢产物四氢-4,5,6,7-噻吩并(3,2-c)吡啶时，这些抗体不发生反应。我们得出结论，药物附着于血小板膜后，噻氯匹定诱导产生的抗体将作为药物载体的血小板破坏。
